Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)

Gabriele Nagel; D Weber; E Fromm; S Erhardt; M Lübbert; W Fiedler; T Kindler; J Krauter; P Brossart; A Kündgen; H R Salih; J Westermann; G Wulf; B Hertenstein; M Wattad; K Götze; D Kraemer; T Heinicke; M Girschikofsky; H G Derigs; H A Horst; C Rudolph; M Heuser; G Göhring; V Teleanu; L Bullinger; F Thol; V I Gaidzik; P Paschka; K Döhner; A Ganser; Hartmut Döhner; R F Schlenk; German-Austrian AML Study Group (AMLSG)

doi:10.1007/s00277-017-3150-3

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)

Standard

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). / Nagel, Gabriele; Weber, D; Fromm, E; Erhardt, S; Lübbert, M; Fiedler, W; Kindler, T; Krauter, J; Brossart, P; Kündgen, A; Salih, H R; Westermann, J; Wulf, G; Hertenstein, B; Wattad, M; Götze, K; Kraemer, D; Heinicke, T; Girschikofsky, M; Derigs, H G; Horst, H A; Rudolph, C; Heuser, M; Göhring, G; Teleanu, V; Bullinger, L; Thol, F; Gaidzik, V I; Paschka, P; Döhner, K; Ganser, A; Döhner, Hartmut; Schlenk, R F; German-Austrian AML Study Group (AMLSG).

In: ANN HEMATOL, Vol. 96, No. 12, 12.2017, p. 1993-2003.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Nagel, G, Weber, D, Fromm, E, Erhardt, S, Lübbert, M, Fiedler, W, Kindler, T, Krauter, J, Brossart, P, Kündgen, A, Salih, HR, Westermann, J, Wulf, G, Hertenstein, B, Wattad, M, Götze, K, Kraemer, D, Heinicke, T, Girschikofsky, M, Derigs, HG, Horst, HA, Rudolph, C, Heuser, M, Göhring, G, Teleanu, V, Bullinger, L, Thol, F, Gaidzik, VI, Paschka, P, Döhner, K, Ganser, A, Döhner, H, Schlenk, RF & German-Austrian AML Study Group (AMLSG) 2017, 'Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)', ANN HEMATOL, vol. 96, no. 12, pp. 1993-2003. https://doi.org/10.1007/s00277-017-3150-3

APA

Nagel, G., Weber, D., Fromm, E., Erhardt, S., Lübbert, M., Fiedler, W., Kindler, T., Krauter, J., Brossart, P., Kündgen, A., Salih, H. R., Westermann, J., Wulf, G., Hertenstein, B., Wattad, M., Götze, K., Kraemer, D., Heinicke, T., Girschikofsky, M., ... German-Austrian AML Study Group (AMLSG) (2017). Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). ANN HEMATOL, 96(12), 1993-2003. https://doi.org/10.1007/s00277-017-3150-3

Vancouver

Nagel G, Weber D, Fromm E, Erhardt S, Lübbert M, Fiedler W et al. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). ANN HEMATOL. 2017 Dec;96(12):1993-2003. https://doi.org/10.1007/s00277-017-3150-3

Bibtex

@article{fe2e010299204810bc4e636b3831d02b,

title = "Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)",

abstract = "We describe genetic and clinical characteristics of acute myeloid leukemia (AML) patients according to age from an academic population-based registry. Adult patients with newly diagnosed AML at 63 centers in Germany and Austria were followed within the AMLSG BiO registry (NCT01252485). Between January 1, 2012, and December 31, 2014, data of 3525 patients with AML (45% women) were collected. The median age was 65 years (range 18-94). The comparison of age-specific AML incidence rates with epidemiological cancer registries revealed excellent coverage in patients < 70 years old and good coverage up to the age of 80. The distribution according to the European LeukemiaNet (ELN) risk categorization from 2010 was 20% favorable, 31% intermediate-1, 28% intermediate-2, and 21% adverse. With increasing age, the relative but not the absolute prevalence of patients with ELN favorable and intermediate-1 risk (p < 0.001), with activating FLT3 mutations (p < 0.001), with ECOG performance status < 2 (p < 0.001), and with HCT-CI comorbidity index < 3 (p < 0.001) decreased. Regarding treatment, obesity and favorable risk were associated with an intensive treatment, whereas adverse risk, higher age, and comorbidity index > 0 were associated with non-intensive treatment or best supportive care. The AMLSG BiO registry provides reliable population-based distributions of genetic, clinical, and treatment characteristics according to age.",

keywords = "Adolescent, Adult, Aged, Aged, 80 and over, Austria, Female, Germany, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Mutation, Registries, fms-Like Tyrosine Kinase 3, Clinical Trial, Journal Article, Multicenter Study",

author = "Gabriele Nagel and D Weber and E Fromm and S Erhardt and M L{\"u}bbert and W Fiedler and T Kindler and J Krauter and P Brossart and A K{\"u}ndgen and Salih, {H R} and J Westermann and G Wulf and B Hertenstein and M Wattad and K G{\"o}tze and D Kraemer and T Heinicke and M Girschikofsky and Derigs, {H G} and Horst, {H A} and C Rudolph and M Heuser and G G{\"o}hring and V Teleanu and L Bullinger and F Thol and Gaidzik, {V I} and P Paschka and K D{\"o}hner and A Ganser and Hartmut D{\"o}hner and Schlenk, {R F} and {German-Austrian AML Study Group (AMLSG)}",

year = "2017",

month = dec,

doi = "10.1007/s00277-017-3150-3",

language = "English",

volume = "96",

pages = "1993--2003",

journal = "ANN HEMATOL",

issn = "0939-5555",

publisher = "Springer",

number = "12",

}

RIS

TY - JOUR

T1 - Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)

AU - Nagel, Gabriele

AU - Weber, D

AU - Fromm, E

AU - Erhardt, S

AU - Lübbert, M

AU - Fiedler, W

AU - Kindler, T

AU - Krauter, J

AU - Brossart, P

AU - Kündgen, A

AU - Salih, H R

AU - Westermann, J

AU - Wulf, G

AU - Hertenstein, B

AU - Wattad, M

AU - Götze, K

AU - Kraemer, D

AU - Heinicke, T

AU - Girschikofsky, M

AU - Derigs, H G

AU - Horst, H A

AU - Rudolph, C

AU - Heuser, M

AU - Göhring, G

AU - Teleanu, V

AU - Bullinger, L

AU - Thol, F

AU - Gaidzik, V I

AU - Paschka, P

AU - Döhner, K

AU - Ganser, A

AU - Döhner, Hartmut

AU - Schlenk, R F

AU - German-Austrian AML Study Group (AMLSG)

PY - 2017/12

Y1 - 2017/12

N2 - We describe genetic and clinical characteristics of acute myeloid leukemia (AML) patients according to age from an academic population-based registry. Adult patients with newly diagnosed AML at 63 centers in Germany and Austria were followed within the AMLSG BiO registry (NCT01252485). Between January 1, 2012, and December 31, 2014, data of 3525 patients with AML (45% women) were collected. The median age was 65 years (range 18-94). The comparison of age-specific AML incidence rates with epidemiological cancer registries revealed excellent coverage in patients < 70 years old and good coverage up to the age of 80. The distribution according to the European LeukemiaNet (ELN) risk categorization from 2010 was 20% favorable, 31% intermediate-1, 28% intermediate-2, and 21% adverse. With increasing age, the relative but not the absolute prevalence of patients with ELN favorable and intermediate-1 risk (p < 0.001), with activating FLT3 mutations (p < 0.001), with ECOG performance status < 2 (p < 0.001), and with HCT-CI comorbidity index < 3 (p < 0.001) decreased. Regarding treatment, obesity and favorable risk were associated with an intensive treatment, whereas adverse risk, higher age, and comorbidity index > 0 were associated with non-intensive treatment or best supportive care. The AMLSG BiO registry provides reliable population-based distributions of genetic, clinical, and treatment characteristics according to age.

AB - We describe genetic and clinical characteristics of acute myeloid leukemia (AML) patients according to age from an academic population-based registry. Adult patients with newly diagnosed AML at 63 centers in Germany and Austria were followed within the AMLSG BiO registry (NCT01252485). Between January 1, 2012, and December 31, 2014, data of 3525 patients with AML (45% women) were collected. The median age was 65 years (range 18-94). The comparison of age-specific AML incidence rates with epidemiological cancer registries revealed excellent coverage in patients < 70 years old and good coverage up to the age of 80. The distribution according to the European LeukemiaNet (ELN) risk categorization from 2010 was 20% favorable, 31% intermediate-1, 28% intermediate-2, and 21% adverse. With increasing age, the relative but not the absolute prevalence of patients with ELN favorable and intermediate-1 risk (p < 0.001), with activating FLT3 mutations (p < 0.001), with ECOG performance status < 2 (p < 0.001), and with HCT-CI comorbidity index < 3 (p < 0.001) decreased. Regarding treatment, obesity and favorable risk were associated with an intensive treatment, whereas adverse risk, higher age, and comorbidity index > 0 were associated with non-intensive treatment or best supportive care. The AMLSG BiO registry provides reliable population-based distributions of genetic, clinical, and treatment characteristics according to age.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Austria

KW - Female

KW - Germany

KW - Humans

KW - Leukemia, Myeloid, Acute

KW - Male

KW - Middle Aged

KW - Mutation

KW - Registries

KW - fms-Like Tyrosine Kinase 3

KW - Clinical Trial

KW - Journal Article

KW - Multicenter Study

U2 - 10.1007/s00277-017-3150-3

DO - 10.1007/s00277-017-3150-3

M3 - SCORING: Journal article

C2 - 29090343

VL - 96

SP - 1993

EP - 2003

JO - ANN HEMATOL

JF - ANN HEMATOL

SN - 0939-5555

IS - 12

ER -